Business Wire

Nerviano Medical Sciences Announces Collaboration and License Agreement with Merck to Discover Small Molecule Inhibitors of Certain Anticancer Targets

Jaa

Today Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, announced an agreement with Merck, a leading science and technology company, under which the two companies will collaborate on the discovery of small molecule inhibitors for development as anticancer agents.

Under the terms of the agreement, Nerviano Medical Sciences grants Merck an exclusive right to conduct joint research and to develop, manufacture and commercialize inhibitors of certain molecular targets in the area of DNA damage repair.

The collaboration between Nerviano Medical Sciences and Merck will initially focus on one target and shall encompass two stages. Nerviano Medical Sciences and Merck will first conduct research work in close collaboration with each other and Merck will subsequently further develop, manufacture and commercialize selected collaboration compounds.

Terms of the multiyear collaboration include an upfront fee in consideration of the rights and licenses granted by Nerviano Medical Sciences to Merck as well as partial funding of the costs incurred by Nerviano Medical Sciences for the conduct of the research program. As additional considerations, Merck shall pay research, development and commercial success milestones, as well as royalties on worldwide sales of products.

“This agreement between Merck and Nerviano Medical Sciences marks a new achievement in our collaboration strategy” - said Andrea Agazzi, Chairman of NMS Group. “We are very excited about the prospect of collaborating with Merck. We believe that by working together and applying our complementary world class research capabilities, we may be able to develop innovative and valuable products for the market.”

“We are thrilled at the prospect of joining forces with Merck in the discovery and development of innovative therapies in the field of defective DNA damage repair mechanisms, which both our teams view to be amongst the most important susceptibilities of cancer to be leveraged in the fight against this disease” - added Arturo Galvani, Head of Discovery Research at Nerviano Medical Sciences. “I believe that this partnership, which combines Nerviano’s expertise in the discovery and development of high-quality drug candidates with Merck’s scientific expertise as a global healthcare leader, is ideally configured for the task of delivering effective new therapies for the care of cancer patients.”

Contact information

Nerviano Medical Sciences
Chiara Lattuada
chiara.lattuada@nmsgroup.it

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 08:00Tiedote

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 07:05Tiedote

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth16.8.2018 02:40Tiedote

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy16.8.2018 01:37Tiedote

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

QConnect – Markkinoiden älykkäin, erittäin kompakti ja lujatekoinen viestintälaite15.8.2018 23:23Tiedote

Quake Global, Inc. (QUAKE), yksi maailman johtavista IoT-markkinoiden toimittajista, julkaisi QConnect™, uuden sukupolven kehittyneen telematiikkalaitteen. Äärimmäisen kompakti QConnect integroituu kiinteisiin ja liikkuviin omaisuuksiin niiden seuraamiseksi, valvomiseksi ja hallitsemiseksi reaaliajassa mistä ja milloin tahansa. Laite tarjoaa useita pitkälle kehitettyjä langattomia kommunikaatiovaihtoehtoja, mukaan lukien LTE/2G/3G, kaksitaajuus-Wi-Fi, Bluetooth/BLE, V2X ja satelliitti. Laite on suunniteltu vastaamaan moniin eri vaatimuksiin yksinkertaisista ja edullisista seurantasovelluksista aina korkean suorituskyvyn monikanavaisiin videon suoratoistosovelluksiin. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20180815005706/fi/ Quake Global’s new QConnect, the most intelligent, global, ultra-compact and rugged communication device available (Photo: Business Wire) QConnect tarjoaa joustavuutta sen ainutlaatuisilla sovell

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 20:43Tiedote

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme